Lunit Highlights Most Up-To-Date Research on Commercial AI Suite for Radiology at RSNA 2022

27 – Dec. 1. The company is presenting eight abstracts highlighting its most up-to-date research on the Lunit INSIGHT suite, an AI solution for radiology.

Since 2016, the company has continued to present findings yearly at RSNA based on its most mature products for radiology - Lunit INSIGHT CXR, an AI solution for chest X-ray, and Lunit INSIGHT MMG, an AI solution for mammography. Lunit has since presented upgraded versions of the two software, now clinically available in 1,000 medical sites across more than 40 countries. Last year, Lunit also showcased a demo version of its brand-new AI solution for Digital Breast Tomosynthesis (Lunt INSIGHT DBT), signaling its expansion of the Lunit INSIGHT product line.

This year's program features seven oral presentations, including studies that aimed to evaluate the performance of Lunit's commercial AI suite for radiology across massive real-world population groups. Presentations based on Lunit INSIGHT CXR include an investigation of the clinical impact of implementing an AI CXR CAD system on the referral rate to chest CT, as well as a study aimed to evaluate the efficacy of a deep learning-based chest CT registration model for pulmonary nodule interval changes. Presentations featuring Lunit INSIGHT MMG include an evaluation of AI as an independent reader for screening mammograms, a study measuring the impact of downsampling of digital mammography images on AI cancer detection, and a study comparing the performance of the Lunit INSIGHT MMG and Lunit INSIGHT DBT.

"Lunit is proud to announce that 7 out of our 8 research studies have been selected for oral presentation at RSNA this year - a meaningful breakthrough in the academic recognition of the developing medical AI field," said Lunit CEO Brandon Suh. "We plan on utilizing this year's meeting to actively interact with our business partners and visitors."

Related Links:
Lunit